Global Life Science Business Partnering (GLSBP) - February 2025

Highlights of Deals in February – 2025

 

1.    Cipla To Invest Rs 415 Crore ($47.50 Million) In South African Arm To Improve Capital Structure.

2.    Alkem acquires Skincare and Med-Device entities for INR 287 crore ($32.84 Million).

3.    Zydus acquires Synthon BV novel cancer drug marketing rights in US.

4.    Granules India acquires Senn Chemicals for $22.10 Million.

5.    Avendus Future Leaders Fund picks minority stake in La Renon for Rs 160 crore ($18.31 Million).

6.    Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India.

7.    Agilus Diagnostics and Lucence collaborate to enhance cancer diagnostics in India.

8.    Healthcare startup Abridge raises $250 Million to enhance AI capabilities. Investors in the funding round included Lightspeed Venture Partners, CVS Health, Redpoint Venture and NVentures.

9.    Lilly pays $10 Million upfront for Organovo’s FXR agonist program

10. Royalty Pharma inks R&D funding deal with Biogen.

11. Tempus Expands AI-Driven Healthcare Platform with Ambry Genetics Acquisition.

12. BridGene nets another Takeda deal amid plans to raise more funding and go public

13. Vanda pharmaceuticals and Anaptys announce exclusive global license agreement for Vanda to develop and commercialize Imsidolimab, an IL-36R Antagonist.

14. Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB.

15. Legacy Pharma acquired InterMune – including US rights to idiopathic pulmonary fibrosis (IPF) drug Esbriet® (pirfenidone) – from Genentech, a subsidiary of Roche.

 

Aagami Updates:

1.     New Client Win: An Illinois company developing innovative therapies for resuscitation from sudden cardiac arrest has appointed Aagami to support their partnering needs.

2.     DCAT week New York City (March 17-20): Our meeting calendar is filling fast with less than 10 open options remaining. If you would like to meet for exploring new possibilities, please contact us very soon.

 

Select Partnering opportunities available:

For Partnering/Licensing/ Co-development:

1.     Seeking Co-development Partner/Investor/EPO supplier for Phase 3 stage Erythropoietin (EPO) asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach)

2.     Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses. Also, Phase 2 trials are starting in Central Africa for MPOX.

3.     Licensing: Several Biosimilars available for Partnering in Japan

a.     Denosumab (Prolia® & Xgeva®)

b.     Romiplostim (Nplate®) [ For immune thrombocytopenia (ITP) ]

c.     Teriparatide (Forteo®/Forsteo®) [ For Osteoporosis ]  

4.     Seeking Acquisition /JV – Clinical stage Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia [Second Human Trial (n=30) ongoing in AU]. Now Leveraging latest in AI.

  1. Seeking Partnering: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – For 1) Depression and ALS 2) Anti-Obesity.

For Acquisition:

1.    Lucrative Opportunity to acquire IP Portfolio (low pricing) of clinical stage First-in-Class Non-Opioid Analgesic.

2.    Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.

3.     US IP/Asset sale: A small molecule NSAID combination for Migraine and other indications using 505(b)(2).

4.     Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU). Now Leveraging the Latest in AI.

Seeking Investment:

  1. Market Ready Nutra portfolio of US client leveraging the latest in AI; Offering stake for $25 Million.
  2. Human-derived, chimeric therapeutic peptide. Phase 2b stage in Atopic Dermatitis. Novel well understood MoA. Strong patent position supportive of various multi-billion- dollar markets and multiple applications, seeking $10 Million.
  3. Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – 1. For Depression and ALS 2. Anti-Obesity. Presently seek $9 Million
  4. Engineering Therapeutics to Block Pathogenic Autoantibodies: Need investment for:
    1. GLP-tox studies
    2. First-in-human trials
    3. Phase II ready Series A raise

Specialized Services

1.     Oligonucleotide and peptides specialist Japanese CDMO for one stop solution to accelerate R&D.

2.     In vivo pharmacology specialists (Mirimus) - Your new partner in Drug Discovery.

Hope you found the content useful. We welcome your feedback and queries.

×
Twitter